AI Model Predicts Age and Detects Disease in Eye Fluid

A group of scientists mapped over 6,000 proteins found in various cell types within the eye using a few drops of eye fluid taken through surgery. Researchers reported that a proteomic clock with an AI model is designed to predict a fit person’s age based on their protein profile. The study was published in the journal Cell on October 19, 2023.

AI Model Predicts Age and Detects Disease in Eye Fluid
Photo of the surgeon. Image Credit: John Barreto

Accelerated aging within specific cell types is linked to diseases like diabetic retinopathy, uveitis and Parkinson’s disease.

What's amazing about the eye is we can look inside and see diseases happening in real time. Our primary focus was to connect those anatomical changes to what’s happening at the molecular level inside the eyes of our patients.

Vinit Mahajan, Surgeon and Professor, Ophthalmology, Stanford University

It is tough to take a sample from the eye of a live patient as it is similar to the brain, which is non-regenerative and can cause permanent damage. An alternative approach involves liquid biopsies, which are samples of fluids collected from the vicinity of the cells or tissues under investigation.

While liquid biopsies can offer insights into the proteins in the targeted region, their capacity to measure a wide array of proteins within small fluid volumes has been restricted. Additionally, they do not provide information about which cells generated specific proteins, which is crucial for disease diagnosis and treatment.

Mahajan’s group—to map protein production by different types of cells within the eye—employed a high-resolution technique to characterize proteins in 120 liquid biopsies collected from the aqueous or vitreous humor of patients undergoing eye surgery.

The team found 5,953 proteins—10 times the number of proteins characterized earlier in similar studies. The investigators traced each protein to particular cell types using a software tool (TEMPO) they created.

AI machine learning model built by researchers predicted the molecular age of healthy eyes accurately based on a subset of 26 proteins. This model also predicted which type of disease is related to particular molecular aging.

The degree of aging increased with the development of the disease and faster by 30 years for individuals with proliferative diabetic retinopathy. The tool also predicts the signs of aging before the clinical symptoms of the original disease occur and is treated in advance.

The researchers also detected various proteins related to Parkinson’s disease. Parkinson’s diagnoses are difficult as the proteins are usually recognized postmortem and current diagnostic methods are not proficient in testing for them. Earlier diagnosis of Parkinson’s disease is possible by screening the markers in eye fluid and later therapeutic monitoring.

The authors say from the findings that aging may be organ or cell-specific, which could lead to advances in precision medicine and clinical trial design.

These findings demonstrate that our organs are aging at different rates. The use of targeted anti-aging drugs could be the next step in preventative, precision medicine.”

Julian Wolf, Study Author and Ophthalmologist, Stanford University

Mahajan says, “If we're going to use molecular therapies, we should be characterizing the molecules in our patients”. He also adds, I think reclassifying patients based on their molecular patterns and which cells are being affected can really improve clinical trials, drug selection, and drug outcomes.

The researchers ensured to illustrate the samples from a large number of patients with a wide range of eye diseases. They also added that this could be used to illustrate the other difficult-to-sample tissues. For instance, liquid biopsies of cerebrospinal fluid could be used to study or diagnose the brain, synovial fluid could be used to study joints, and urine could be used to study the kidneys.

Source:
Journal reference:

Wolf, J., et al. (2023). Liquid-biopsy proteomics combined with AI identifies cellular drivers of eye aging and disease in vivo.  Cell. doi.org/10.1016/j.cell.2023.09.012.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unveiling Cannabinoid’s Potential for Treating Age-Related Brain Degeneration